Proof‐of‐concept for incorporating mechanistic insights from multi‐omics analyses of polymyxin B in combination with chloramphenicol against Klebsiella pneumoniae

Carbapenemase‐resistant Klebsiella pneumoniae (KP) resistant to multiple antibiotic classes necessitates optimized combination therapy. Our objective is to build a workflow leveraging omics and bacterial count data to identify antibiotic mechanisms that can be used to design and optimize combination regimens. For pharmacodynamic (PD) analysis, previously published static time‐kill studies (J Antimicrob Chemother 70, 2015, 2589) were used with polymyxin B (PMB) and chloramphenicol (CHL) mono and combination therapy against three KP clinical isolates over 24 h. A mechanism‐based model (MBM) was developed using time‐kill data in S‐ADAPT describing PMB‐CHL PD activity against each isolate. Previously published results of PMB (1 mg/L continuous infusion) and CHL (Cmax: 8 mg/L; bolus q6h) mono and combination regimens were evaluated using an in vitro one‐compartment dynamic infection model against a KP clinical isolate (108 CFU/ml inoculum) over 24 h to obtain bacterial samples for multi‐omics analyses. The differentially expressed genes and metabolites in these bacterial samples served as input to develop a partial least squares regression (PLSR) in R that links PD responses with the multi‐omics responses via a multi‐omics pathway analysis. PMB efficacy was increased when combined with CHL, and the MBM described the observed PD well for all strains. The PLSR consisted of 29 omics inputs and predicted MBM PD response (R2 = 0.946). Our analysis found that CHL downregulated metabolites and genes pertinent to lipid A, hence limiting the emergence of PMB resistance. Our workflow linked insights from analysis of multi‐omics data with MBM to identify biological mechanisms explaining observed PD activity in combination therapy.

[1]  Matthew D. Johnson,et al.  Synergy of the Polymyxin-Chloramphenicol Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae Is Predominately Driven by Chloramphenicol. , 2021, ACS infectious diseases.

[2]  Neang S. Ly,et al.  Moving From Point‐Based Analysis to Systems‐Based Modeling: Integration of Knowledge to Address Antimicrobial Resistance Against MDR Bacteria , 2021, Clinical pharmacology and therapeutics.

[3]  J. Li,et al.  Evaluation Strategies for Triple‐Drug Combinations against Carbapenemase‐Producing Klebsiella Pneumoniae in an In Vitro Hollow‐Fiber Infection Model , 2021, Clinical pharmacology and therapeutics.

[4]  Amy K. Cain,et al.  The Transcriptomic Signature of Tigecycline in Acinetobacter baumannii , 2020, Frontiers in Microbiology.

[5]  Matthew D. Johnson,et al.  Transcriptomic responses of a New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae isolate to the combination of polymyxin B and chloramphenicol. , 2020, International journal of antimicrobial agents.

[6]  Brian T. Tsuji,et al.  Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae , 2020, Antimicrobial Agents and Chemotherapy.

[7]  K. Ko,et al.  Effect of colistin-based antibiotic combinations on the eradication of persister cells in Pseudomonas aeruginosa. , 2020, The Journal of antimicrobial chemotherapy.

[8]  C. L. Cardoso,et al.  Synergistic activity of polymyxin B combined with vancomycin against carbapenem‐resistant and polymyxin‐resistant Acinetobacter baumannii: first in vitro study , 2019, Journal of medical microbiology.

[9]  K. Holt,et al.  Klebsiella pneumoniae as a key trafficker of drug resistance genes from environmental to clinically important bacteria. , 2018, Current opinion in microbiology.

[10]  M. Ouellette,et al.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. , 2017, The Lancet. Infectious diseases.

[11]  G. Rao,et al.  Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae , 2017, Antimicrobial Agents and Chemotherapy.

[12]  C. Landersdorfer,et al.  Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes , 2017, Antimicrobial Agents and Chemotherapy.

[13]  Salman Motlekar,et al.  Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence , 2017, Critical care research and practice.

[14]  I. Androulakis,et al.  Understanding Physiology in the Continuum: Integration of Information from Multiple -Omics Levels , 2017, Front. Pharmacol..

[15]  Neang S. Ly,et al.  Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes. , 2017, International journal of antimicrobial agents.

[16]  R. Hancock,et al.  Polymyxin: Alternative Mechanisms of Action and Resistance. , 2016, Cold Spring Harbor perspectives in medicine.

[17]  Neang S. Ly,et al.  Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. , 2016, International journal of antimicrobial agents.

[18]  M. Gustafsson,et al.  Facing the challenges of multiscale modelling of bacterial and fungal pathogen–host interactions , 2016, Briefings in functional genomics.

[19]  Matthew D. Johnson,et al.  Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two 'old' antibiotics-polymyxin B and chloramphenicol. , 2015, The Journal of antimicrobial chemotherapy.

[20]  Brian T. Tsuji,et al.  Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use , 2015, Pharmacotherapy.

[21]  Kidakan Saithanu,et al.  CUTOFF THRESHOLD OF VARIABLE IMPORTANCE IN PROJECTION FOR VARIABLE SELECTION , 2014 .

[22]  M. Falagas,et al.  Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections , 2014, Emerging infectious diseases.

[23]  M. Antonelli,et al.  Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria , 2013, Antimicrobial Agents and Chemotherapy.

[24]  N. Zenkin,et al.  Molecular mechanism of bacterial persistence by HipA. , 2013, Molecular cell.

[25]  M. Falagas,et al.  Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence , 2013, Antimicrobial Agents and Chemotherapy.

[26]  R. Nation,et al.  Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. , 2013, Future microbiology.

[27]  C. Landersdorfer,et al.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  D. Paterson,et al.  Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens , 2012, Antimicrobial Agents and Chemotherapy.

[29]  Alimuddin Zumla.  Mandell, Douglas, and Bennett's principles and practice of infectious diseases , 2010, The Lancet Infectious Diseases.

[30]  C. Herrera,et al.  Activation of PmrA inhibits LpxT-dependent phosphorylation of lipid A promoting resistance to antimicrobial peptides , 2010, Molecular microbiology.

[31]  D. Calfee,et al.  Decreased Susceptibility to Polymyxin B during Treatment for Carbapenem-Resistant Klebsiella pneumoniae Infection , 2009, Journal of Clinical Microbiology.

[32]  J. Abranches,et al.  The Molecular Alarmone (p)ppGpp Mediates Stress Responses, Vancomycin Tolerance, and Virulence in Enterococcus faecalis , 2009, Journal of bacteriology.

[33]  J. Li,et al.  Pharmacokinetics of intravenous polymyxin B in critically ill patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Joel T. Smith,et al.  The global, ppGpp‐mediated stringent response to amino acid starvation in Escherichia coli , 2008, Molecular microbiology.

[35]  J. Rahal.  Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  E. Groisman,et al.  The PmrA-Regulated pmrC Gene Mediates Phosphoethanolamine Modification of Lipid A and Polymyxin Resistance in Salmonella enterica , 2004, Journal of bacteriology.

[37]  Alan Forrest,et al.  Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin , 2004, Antimicrobial Agents and Chemotherapy.

[38]  S. Wold,et al.  PLS-regression: a basic tool of chemometrics , 2001 .

[39]  T. Johns,et al.  Laboratory guidelines for monitoring of antimicrobial drugs , 1998 .

[40]  P. Ambrose.  Clinical Pharmacokinetics of Chloramphenicol and Chloramphenicol Succinate , 1984, Clinical pharmacokinetics.

[41]  R. Slaughter,et al.  Chloramphenicol Pharmacokinetics in Hospitalized Patients , 1979, Antimicrobial Agents and Chemotherapy.

[42]  Y. Sokawa,et al.  Relaxation effect of chloramphenicol on the stringent control in Escherichia coli. , 1978, Journal of biochemistry.

[43]  J. Gallant,et al.  On the turnover of ppGpp in Escherichia coli. , 1972, The Journal of biological chemistry.

[44]  R. M. Smith,et al.  Chloromycetin, a New Antibiotic From a Soil Actinomycete. , 1947, Science.

[45]  O. Zusman,et al.  Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis , 2017, The Journal of antimicrobial chemotherapy.

[46]  Brad Spellberg,et al.  The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  J. Mouton.  Combination therapy as a tool to prevent emergence of bacterial resistance , 1999, Infection.